|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16.09.25 - 15:03
|
ClostraBio Announces Key Milestones: Board Appointment of Industry Veteran Scott Ravech and Publication of CLB101™ Safety Data (Business Wire)
|
|
|
CHICAGO--(BUSINESS WIRE)--ClostraBio, Inc., a biotech company pioneering microbiome-based solutions for gastrointestinal health, today announced two major milestones: the appointment of Scott Ravech, former CEO of Deerland Probiotics & Enzymes, to its Board of Directors, and the peer-reviewed publication of toxicology data validating the safety of its lead ingredient, Anaerostipes caccae CLB101™. These achievements set the stage for the company's commercial launch later this month with a leading health-care practitioner-focused dietary supplement brand partner.
Industry Veteran Joins Board
Scott Ravech brings more than 20 years of leadership experience in probiotics and dietary supplements. As CEO of Deerland, he guided the company through rapid growth and its acquisition by Archer Daniels Midland (ADM). He has advised ClostraBio for the past two years, providing strategic input on product development, regulatory pathways, manufacturing, and commercialization.
“Scott has already played an instrumenta...
|
|
|
|
|
|
|
|